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Abstract
Objectives—Numerous studies have documented disparities in health care utilization between
non-Hispanic White and minority elders. We investigated differences in anti-dementia medication
use between non-Hispanic White and minority community-dwelling Medicare beneficiaries with
dementia.
Methods—Using multivariate analysis with generalized estimating equations, we estimated
prevalence ratios (PRs) for anti-dementia medication use by race/ethnicity for 1,120 beneficiaries
with dementia from years 2001 through 2003 of the Medicare Current Beneficiary Survey.
Results—After adjusting for demographics, socioeconomics, health care access and utilization,
comorbidities, and service year, we found that anti-dementia medication use was approximately
30% higher among non-Hispanic Whites compared to other racial/ethnic groups (PR = 0.73, 95%
confidence interval [CI] = 0.59, 0.91). As for individual racial/ethnic groups, prevalence
disparities remained significant for non-Hispanic Blacks (PR = 0.75, 95% CI = 0.57, 0.99) and
non-Hispanic others (PR = 0.50, 95% CI = 0.26, 0.96) but were attenuated for Hispanics (PR =
0.84, 95% CI = 0.59, 1.20).
Discussion—Results provide evidence that racial/ethnic disparities in utilization of drugs used
to treat dementia exist and are not accounted for by differences in demographic, economic, health
status, or health utilization factors. Findings provide a foundation for further research that should
use larger numbers of minority patients and consider dementia type and severity, access to
specialty dementia care, and cultural factors.
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IN general, disease burden falls disproportionately on minority populations. Even at older
ages, minorities tend to have poorer health status, whether measured by disease incidence,
prevalence, or severity (National Center for Health Statistics, 2007). Eliminating health
disparities is one of two overarching goals of Healthy People 2010 (U.S. Department of
Health and Human Services, 2000), the disease prevention and health promotion agenda of
the U.S. Department of Health and Human Services. The Institute of Medicine’s 2002
ground-breaking report Unequal Treatment: Confronting Racial and Ethnic Disparities in
Health Care (Smedley, Stith, & Nelson, 2003) and the National Healthcare Disparities
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Report (Agency for Healthcare Research and Quality, 2006) documented disparities in
health care access. Disparities extend to inequalities in access to medications. Older
minorities are less likely than majority elders to utilize prescription drugs or to increase their
numbers of prescriptions over time (Briesacher, Limcangco, & Gaskin, 2003).
Dementia is a chronic and serious disease, with an estimated worldwide societal cost of
$315.4 billion in 2005 (Wimo, Winblad, & Jonsson, 2007). According to findings from the
2002 Medicare Current Beneficiary Survey (MCBS), approximately 3.4 million Medicare
beneficiaries are diagnosed with Alzheimer’s disease and related disorders, more than half
of whom (approximately 2 million) live in the community (Gruber-Baldini, Stuart,
Zuckerman, Simoni-Wastila, & Miller, 2007; Stuart et al., 2007). Non-Hispanic Blacks with
dementia are more likely to be undiagnosed or misdiagnosed relative to non-Hispanic
Whites (Clark et al., 2005; Leo, Narayan, Sherry, Michalek, & Pollock, 1997); however,
with population-based sampling and careful diagnostic techniques employing neuro-
psychological and laboratory testing following National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria, the prevalence of dementia may be relatively
higher in minority populations. One community-based survey, with diagnoses confirmed
using clinical testing and NINCDS-ADRDA criteria, found the prevalence of Alzheimer’s
disease among African American men to be 2.5 times greater than the prevalence among
non-Hispanic White men (Demirovic et al., 2003). Both non-Hispanic Blacks and Latinos
transition to long-term care at more advanced stages of dementia (Stevens et al., 2004; Yaffe
et al., 2002).
Minorities also may be less likely to be prescribed anti-dementia medications. One study
found that, considered together, minority patients (non-Hispanic Blacks, Asians, and
Latinos) in Alzheimer’s disease research centers in California had 40% lower odds of
acetylcholinesterase inhibitor use compared to Whites (Mehta, Yin, Resendez, & Yaffe,
2005). Thus, there may be racial/ethnic disparities in dementia incidence, prevalence, access
to health care services, and health care utilization.
The U.S. Food and Drug Administration has approved two classes of drugs to treat
symptoms of cognitive deficit in Alzheimer’s disease and related disorders: cholinesterase
inhibitors (donepezil, rivastigmine, galatamine, and tacrine) and an N-methyl-D-aspartate
receptor antagonist (memantine). Using a national data set of community-dwelling Medicare
beneficiaries, we investigated the use of these prescription anti-dementia medications to
compare prevalence by non-Hispanic White or minority race/ethnicity.
Methods
Data Source
The study sample consisted of 1,606 person-years of observation of 1,120 community-
dwelling Medicare beneficiaries with a reported diagnosis of dementia from the MCBS for
years 2001 through 2003. The MCBS is a continuous sample of U.S. Medicare recipients
conducted by the Centers for Medicare & Medicaid Services. Although the use of sampling
weights for single years of the MCBS would allow it to be nationally representative of
Medicare beneficiaries, we could not use weights in our analysis because individuals may
have crossed years. Furthermore, because the MCBS oversamples certain groups (e.g., those
younger than 65 years of age), our unweighted sample was not necessarily representative of
Medicare beneficiaries as a whole. The MCBS uses a rotating panel design; beneficiaries or
their proxies are interviewed in their homes three times per year for a maximum of 4 years
by using computer-assisted personal interviewing technology. Respondents are asked a
battery of questions relating to demographic characteristics, health status, pharmaceutical
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and other health care utilization and expenditures, and health insurance coverage. The
MCBS links survey information to Medicare Parts A and B claims that contain diagnostic
indicators as well as payment information. We excluded 42 observations from the analysis
because of a missing value; all observations analyzed had complete information.
Measures
The dependent variable was the annual prevalence of use of any anti-dementia medication,
namely donepezil (Aricept®), rivastigmine (Exelon®), galantamine (Razadyne®/
Reminyl®), or memantine (Namenda®), by non-Hispanic Whites and minorities.
Respondents self-reported medication use. In addition to querying respondents about
specific medications used, interviewers reviewed medication containers as part of the thrice-
yearly in-home interview during Years 2, 3, and 4. Respondents were asked to keep all
medication containers, insurance slips, and receipts for medications, and the interviewers
reviewed these materials at each interview. If a medication named in a previous round of
interviewing was not listed, the respondent was queried about its use during the period.
Thus, prescription fills were recorded, but actual medication use was not observed. We
determined race/ethnicity, our variable of interest, from the self-report from the in-home
computer-assisted personal interviewing interview. We determined dementia diagnosis
status from the presence of International Classification of Diseases–9 codes 331.0, 331.1,
331.2, 331.7, 290.xx (excluding 290.8 and 290.9), 294.xx (excluding 294.9), or 794.xx on
one or more inpatient hospital, skilled nursing facility, home health, hospital outpatient, or
physician supplier/carrier claim or from self-/proxy report (“sample person ever told had
Alzheimer’s disease or dementia”). We determined dementia status from claims alone for
49.9% of respondents, from self-reports only for 23.7%, and from both sources for 26.4%.
We chose covariates from a literature review and from preliminary analysis. Covariates
included age (less than 65 years, 65–74, 75–84 and 85 years and older), gender, U.S. census
region, residence in a metropolitan statistical area, income, education, marital status, source
of dementia diagnosis (claims data, self-/proxy report, or both), source of survey information
(self-report or proxy respondent for at least half of the interviews), prescription drug
insurance coverage, use of other medication classes, and year of observation. We estimated
comorbid disease burden by using a count of comorbid disease classes.
Analysis
We compared use or nonuse of anti-dementia medications by using chi-square tests and t
tests. Multivariate analysis with generalized estimating equations (GEE) estimated the
conditional effect of race/ethnicity on anti-dementia drug use, controlling for the covariates
listed above. This analysis yielded prevalence ratios (PRs) rather than prevalence odds
ratios. With 26% of the sample using medication, odds ratios would not have been an
accurate estimation of actual prevalence. Odds ratios are always further from the null value
of 1.0 with the disparity increasing with higher prevalence (Rothman & Greenland, 1998).
GEE is especially useful for investigations with binary outcomes and correlated data. With
efficient parameter estimation and accurate standard errors, GEE is better at correcting for
clustering and other types of correlation (Hanley, Negassa, Edwardes, & Forrester, 2003).
Standard errors are recalibrated to account for similarity of measures, or correlation, by the
same individual across differing lengths of observation (Fitzmaurice, Laird, & Ware, 2004).
Logistic regression analysis is less suited to this analysis. Logistic regression does not
consider nonindependence due to correlation; it also yields prevalence odds ratios rather
than PRs and thus would have overestimated the association of race/ethnicity and
medication use. We assumed a binomial distribution and used a log link function to report
PRs. We calculated PRs and their associated 95% confidence intervals (CIs) by using PROC
GENMOD in SAS 9.1.3 (Deddens, Petersen, & Lei, 2003). Because the usual tests of model
fit are not valid for GEE models, we assessed goodness of fit by using an experimental
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technique based on aggregates of residuals with an associated p value of .9060, indicating a
satisfactory model (SAS Institute, 2003).
Results
The ethnic/racial distribution of the sample was 76.3% non-Hispanic White, 11.7% non-
Hispanic Black, 8.1% Hispanic, and 3.8% non-Hispanic other (see Table 1). The mean age
of the sample was 80 years (SD = 11), and nearly 60% were female. Approximately 26% of
the sample received at least one anti-dementia medication, most commonly donepezil and
less frequently rivastigmine, galantamine, or memantine. The sample differed significantly
by race for anti-dementia medication use, age, income, education, marital status, region,
urban residence, and proxy response. Whites most often used anti-dementia medication
(28.7%, p = .0022), were in the highest income group (27.7%, p, < .0001), had education
beyond high school (35.1%, p < .0001), and were currently married (45.6%, p < .0001);
Hispanics most often were younger than 65 years of age (19.8%, p < .0001), lived in urban
metropolitan areas (91.2%, p < .0018), lived in the South (68.1%, p < .0001), and had a
proxy respondent for at least half of the interviews (57.1%, p = .0011).
In addition to the race/ethnicity comparisons shown in Table 1, we also performed bivariate
comparisons between anti-dementia medication users and nonusers (data not shown).
Compared to those not receiving anti-dementia medication, anti-dementia medication users
were older (M 81.3 years vs 79.7, t=−2.89, p .0040), were more often currently married
(53.6% vs 38.5%, χ2 = 40.2, p < .0001), used more cardiovascular (80.1% vs 74.1%, χ2 =
4.2, p = .0401) and antidepressant medications (38.1% vs 29.1%, χ2 = 8.2, p = .0041), more
frequently had prescription drug insurance (79.4% vs 71.1%, χ2 = 7.6, p = .0058), and were
more likely to have their dementia status ascertained both from claims data and from self-
report (52.2% vs 17.4%, χ2 = 134.7, p < .0001). Relative to nonusers, anti-dementia
medication users were less likely to use the services of hospitals (27.9% vs 40.4%, χ2 =
14.6, p=.0001), hospices (2.1% vs 6.9%, χ2=9.4, p=.0022), or skilled nursing facilities (7.2%
vs 15.0%, χ2 = 11.5, p = .0007). They were also less likely to live in poverty (13.1% vs
27.0%, χ2 = 24.7, p < .0001). There were no other significant differences between
medication users and nonusers.
We compared the prevalence of anti-dementia medication by racial/ethnic group (see Table
2). In the unadjusted model, the PR comparing all minorities to non-Hispanic Whites was
0.61 (95% CI = 0.48, 0.77). The adjusted model included demographics (gender, age,
marital status, and geographic location), socioeconomic status (income and education),
source of diagnosis (claims data, self-report, or both), self- or proxy reporting, comorbidity
count, health care utilization variables (prescription insurance status, hospital, skilled
nursing facility and hospice stay, use of other drug classes), and year. The PR for the
adjusted model was 0.73 (95% CI = 0.59, 0.91). In the final model, urban or suburban
residence (PR = 1.30, 95% CI = 1.09, 1.57) and use of other drug classes (PR = 1.50, 95%
CI = 1.16, 1.95) were associated with higher prevalence of use. Being never married,
divorced, or separated (PR = 0.33, 95% CI = 0.17, 0.61); having a single source for
dementia diagnosis (PR = 0.37, 95% CI = 0.31, 0.44, for claims data only; PR = 0.35, 95%
CI = 0.28, 0.44, for self-report only); being a proxy respondent rather than a self-report (PR
= 0.82, 95% CI = 0.71, 0.95); lacking supplemental prescription insurance coverage (PR =
0.76, 95% CI = 0.63, 0.92); and using hospice services (PR = 0.49, 95% CI = 0.27, 0.89)
predicted lower prevalence of anti-dementia drug use. We repeated the analyses with
individual minority racial/ethnic groups entered simultaneously in both models (see Table
3). Prevalence disparities remained significant for non-Hispanic Blacks (PR = 0.75, 95% CI
= 0.57, 0.99) and non-Hispanic others (PR = 0.50, 95% CI = 0.26, 0.96) but were attenuated
for Hispanics (PR = 0.84, 95% CI = 0.59, 1.20).
Zuckerman et al. Page 4














Relative to non-Hispanic Whites, community-dwelling minority Medicare beneficiaries with
dementia had an approximately 30% lower prevalence of anti-dementia medication use in
the years 2001 through 2003. The finding of lower prevalence among minority Medicare
beneficiaries was extremely robust, persisting even after we adjusted for demographic,
economic, health status, health care access, and utilization factors. Our findings are similar
in magnitude to the 40% lower prevalence for non-Whites found by Mehta and colleagues
(2005) in their investigation of acetylcholinesterase inhibitor use in California Alzheimer’s
disease centers in the years 1999 through 2003. Our study reinforces their findings by using
a national community-dwelling sample rather than one from a specialty clinical setting.
When we examined racial/ethnic groups individually, PRs remained statistically significant
for non-Hispanic Blacks and non-Hispanic others but lost significance for Hispanics,
possibly because of the small numbers in each minority group. Of interest is that the
smallest group, the heterogeneous “non-Hispanic other” category, had the greatest disparity
in prevalence. In our sample, the 43 non-Hispanic others included those reporting more than
one race/ethnicity (n = 16), Asian or Pacific Islander (n = 15), North American native (n =
7), don’t know (n = 3), and other (n = 2). Numbers were too small within this group to
determine whether prevalence was similar across these subcategories or whether one or two
subcategories strongly influenced the disparity.
Although we cannot fully explain this disparity from our investigation, our findings suggest
that between-race differences are not due to demographic, economic, health status, access,
or utilization variables. Disparities may be due to differences in attitudes toward dementia in
diverse cultures in the United States, as well as cultural bias in cognitive measurement
(Manly & Espino, 2004). They might arise also from differences in psychosocial
environment (e.g., neighborhood effects) or discrimination experienced by members of
minority groups, both of which have been proposed to be important determinants of the
mental health of non-Hispanic Blacks (Williams & Earl, 2007). If dementia is less often
correctly diagnosed in minorities, as reported by Clark and colleagues (2005) and Leo and
associates (1997), our disparity findings may underestimate the unmet treatment need
among minorities with dementia that has not been diagnosed.
Differences in prescribing patterns for non-Hispanic Whites and other groups might arise in
several ways. Minority patients have relatively poorer access to health care, beyond the
variation in hospital, skilled nursing facility, and hospice use and prescription drug
insurance coverage accounted for by this analysis (Smedley et al., 2003). Less contact with
physicians would likely result in fewer prescriptions being written. In our sample, non-
Hispanic Whites had an average of 7.7 office visits during the observation period, whereas
minorities made 6.9 visits; this difference is nearly statistically significant at the α = .05
level (t =−1.90, p = .058). Additionally, minority elders are placed in long-term care at more
advanced stages of dementia (Stevens et al., 2004; Yaffe et al., 2002), perhaps leading to a
disproportionate number of more severely demented minority elders remaining in the
community. With the exception of memantine, approved in 2003 for moderate to severe
dementia of the Alzheimer’s type, anti-dementia medications were indicated for use in only
mild to moderate disease during our study years (U.S. Food and Drug Administration,
2003); therefore, medication might have been considered inappropriate for community-
dwelling minority elders with more advanced dementia and thus not prescribed.
Non-Hispanic Blacks make proportionately more mental health visits to primary care
providers rather than to specialists and thus receive fewer prescriptions for psychotropics
(Snowden, 2001). Poorer access to specialty dementia care may explain some of the
disparity with regard to dementia medications. In addition, non-Hispanic Blacks have higher
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relative rates of vascular dementia, and medications considered in this investigation were
approved for use in Alzheimer’s disease rather than for vascular and other types of dementia
during the study years. Thus, non-Hispanic Blacks in particular may have received
proportionately fewer prescriptions for anti-dementia medications, because the use of these
medications was not indicated for dementia types other than Alzheimer’s disease. However,
even if taken together, it seems unlikely that dementia type and disease severity could
account for the entire 30% differential between majority and minority use of anti-dementia
medications.
Our study has several limitations. Specific anti-dementia medications and their indications
changed within the study years 2001 through 2003 and continue to do so; therefore, findings
relating to this class of medications during those years may not hold true for the present or
future. Numbers within each specific race/ethnicity group were relatively small; thus, our
ability to look at individual groups is limited. We lacked information on caregivers of people
with dementia. Caregiver factors may have influenced access to health care for people with
dementia; for instance, caregiver psychological distress is associated with a decreased
likelihood of receipt of influenza vaccine by the person being cared for (Thorpe et al., 2006).
Issues of disparities need investigation using data sources that contain higher numbers of
minorities, thereby allowing for detailed examination of prevalence and use patterns by
specific racial and ethnic populations. Further investigation needs to be undertaken with
larger numbers of minority participants, accounting for issues of dementia type and severity,
medication dose and duration of use, access to specialty dementia care, and consistency in
treatment disparities across settings of care. As well, dementia prevalence is greatest in
nursing homes and other institutions, and evaluation of racial and ethnic disparities should
be considered in this vulnerable population, especially because a recent study reported
significant racial disparities in quality nursing home placement (Smith, Feng, Fennell, Zinn,
& Mor, 2007). Additionally, the influence of cultural and environmental factors in dementia
treatment remains a fertile area worthy of future exploration.
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Characteristic n (%) n (%) n (%) n (%) n (%)
Use of any anti-dementia drug (p = .0022) 245 (28.7) 26 (19.9) 15 (16.5) 5 (11.6) 291 (26.0)
Male gender 365 (42.7) 42 (32.1) 34 (37.4) 14 (32.6) 455 (40.6)
Age (p < .0001)
  Less than 65 years 33 (3.9) 5 (3.8) 18 (19.8) 5 (11.6) 61 (5.5)
  65–74 years 135 (15.8) 23 (17.6) 17 (18.7) 8 (18.6) 183 (16.3)
  75–84 years 383 (44.8) 52 (39.7) 23 (25.3) 16 (37.2) 474 (42.3)
  85 years or more 304 (35.6) 51 (38.9) 33 (36.3) 14 (32.6) 402 (35.9)
Income (p < .0001)
  100% FPL or less 130 (15.2) 64 (48.9) 52 (57.1) 16 (37.2) 262 (23.4)
  101%–149% FPL 187 (21.9) 35 (26.7) 20 (22.0) 10 (23.4) 252 (22.5)
  150%–300% FPL 301 (35.2) 29 (22.1) 15 (16.5) 9 (20.9) 354 (31.6)
  More than 300% FPL 237 (27.7) 3 (2.3) 4 (4.4) 8 (18.6) 252 (22.5)
Education (p < .0001)
  0–8 years 164 (19.2) 59 (45.0) 46 (50.6) 10 (23.3) 279 (24.9)
  9–12 years (no high school graduation) 146 (17.1) 38 (29.0) 18 (19.8) 4 (9.3) 206 (18.4)
  High school graduate 28.7 (18.7) 18 (13.7) 16 (17.6) 15 (34.9) 294 (26.3)
  Postsecondary education 300 (35.1) 16 (12.2) 11 (12.1) 14 (32.6) 341 (30.5)
Marital status (p < .0001)
  Currently married 390 (45.6) 35 (26.7) 33 (36.3) 17 (39.5) 475 (42.4)
  Widowed 389 (45.5) 79 (60.3) 35 (38.5) 20 (46.5) 523 (46.7)
  Never married/divorced/separated 76 (8.9) 17 (13.0) 23 (25.3) 6 (14.0) 122 (10.9)
Region (p < .0001)
  East 181 (21.2) 16 (12.2) 10 (11.0) 3 (7.0) 210 (18.8)
  Midwest 191 (22.3) 20 (15.3) 4 (4.4) 7 (16.3) 222 (19.8)
  South 325 (38.0) 85 (64.9) 62 (68.1) 12 (27.9) 484 (43.2)
  West 158 (18.5) 10 (7.6) 15 (16.5) 21 (48.8) 204 (18.2)
Residence in urban MSA (p = .0008) 615 (71.9) 91 (69.5) 83 (91.2) 31 (72.1) 820 (73.2)
Proxy respondent for half or more interviews (p = .
0011) 328 (38.4) 62 (47.3) 52 (57.1) 22 (51.2) 464 (41.4)
Source of diagnosis information
  Claims data only 436 (51.0) 60 (45.8) 43 (47.3) 20 (46.5) 559 (49.9)
  Self-/proxy report only 192 (22.5) 36 (27.5) 24 (26.4) 13 (30.2) 265 (23.7)
  Both claims and self-/proxy report 227 (26.6) 35 (26.7) 24 (26.4) 10 (23.3) 296 (26.4)
Prescription drug insurance coverage 631 (73.8) 91 (69.5) 65 (71.4) 33 (76.7) 820 (73.2)
Hospitalized during study period 318 (37.2) 51 (38.9) 31 (34.1) 16 (37.2) 416 (37.1)
SNF stay during study period 116 (13.6) 15 (11.5) 8 (8.8) 6 (14.0) 145 (13.0)
Hospice utilization during period 46 (5.4) 10 (7.6) 3 (3.3) 4 (9.3) 63 (5.6)




























Characteristic n (%) n (%) n (%) n (%) n (%)
Number of comorbid disease classes
  0–4 190 (22.2) 37 (28.2) 27 (29.7) 10 (23.3) 264 (23.6)
  5–6 151 (17.7) 28 (21.4) 12 (13.2) 12 (27.9) 203 (18.1)
  7–10 271 (31.7) 34 (26.0) 22 (24.2) 11 (25.6) 338 (30.2)
  11 or more 243 (28.4) 32 (24.4) 30 (33.0) 10 (23.3) 315 (28.1)
Use of other drug classesa 711 (83.2) 112 (85.5) 70 (76.9) 33 (76.7) 956 (82.7)
Year
  2001 261 (30.5) 34 (26.0) 27 (29.7) 9 (20.9) 331 (29.6)
  2002 237 (27.7) 42 (32.1) 28 (30.8) 14 (32.6) 321 (28.7)
  2003 357 (41.8) 55 (42.0) 36 (39.6) 20 (46.5) 468 (41.8)
Notes: FPL = federal poverty level; MSA = metropolitan statistical area; SNF = skilled nursing facility.
p ≥ .05 except where shown.
aCardiovascular, antidepressant, or antipsychotic medication.
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Table 2
Multivariate Analysis of Prevalence Ratios for Anti-Dementia Medications for Non-Hispanic White Versus
Minority Medicare Beneficiaries (N = 1,606 person-years of observation)
Unadjusted Model Adjusted Model
Variable PR 95% CI PR 95% CI
Minority race vs non-Hispanic
  White 0.61 0.48, 0.77 0.73 0.59, 0.91
Agea
  Less than 65 years 0.45 0.18, 1.09
  65-74 years 0.99 0.78, 1.26
  75-84 years 1.01 0.86, 1.20
Female gender 0.99 0.85, 1.14
Regionb
  North 0.93 0.72, 1.21
  South 1.17 0.94, 1.44
  Midwest 1.04 0.85, 1.28
Urban/suburban residence 1.30 1.09, 1.57
Income levelc
  100% FPL or less 0.83 0.63, 1.09
  101%–149% FPL 0.96 0.77, 1.20
  150%–300% FPL 0.93 0.80, 1.08
Educationd
  8 years or fewer 1.00 0.93, 1.07
  9–12 years (no high
   school graduation) 0.94 0.79, 1.12
  High school graduate 0.94 0.81, 1.10
Marital statuse
  Widowed 0.90 0.77, 1.06
  Never married/divorced/separated 0.33 0.17, 0.61
Proxy respondent 0.82 0.71, 0.95
Source of diagnosisf
  Claims data only 0.37 0.31, 0.44
  Self-/proxy report only 0.35 0.28, 0.44
Number of comorbid conditionsg
  0–4 1.09 0.89, 1.33
  5–6 1.08 0.88, 1.32
  7–10 1.09 0.89, 1.34
No supplemental prescription drug
  coverage 0.76 0.63, 0.92
Hospital stay 0.97 0.80, 1.20
Skilled nursing facility stay 0.74 0.54, 1.02
Hospice stay 0.51 0.28, 0.92
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Unadjusted Model Adjusted Model
Variable PR 95% CI PR 95% CI
Use of other drug classesh 1.50 1.16, 1.95
Yeari
  2001 0.97 0.85, 1.12
  2002 0.88 0.77, 1.01
Notes: PR = prevalence ratio; CI = confidence interval; FPL = federal poverty level.
a85 years or older is the reference group.
b
East is the reference group.
cGreater than 300% FPL is the reference group.
d
Postsecondary education is the reference group.
eCurrently married is the reference group.
f
Diagnosis from both claims data and self-report is the reference group.
g11 or more comorbid conditions is the reference group.
hCardiovascular, antidepressant, or antipsychotic medications.
i2003 is the reference group.
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Table 3
Multivariate Analysis of Prevalence Ratios for Anti-Dementia Medications for Non-Hispanic White Versus
Specific Racial/Ethnic Groups of Medicare Beneficiaries
Unadjusted Model Adjusted Model
Group PR 95% CI PR 95% CI
Non-Hispanic Blacks 0.68 0.50, 0.91 0.75 0.57, 0.99
Hispanics 0.61 0.43, 0.88 0.84 0.59, 1.20
Non-Hispanic Other 0.38 0.19, 0.77 0.50 0.26, 0.96
Note: Non-Hispanic Whites is the reference group. PR = prevalence ratio; CI = confidence interval.
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